Pharmaceutical Cannabis - South Korea

  • South Korea
  • South Korea's revenue in the Pharmaceutical Cannabis sector is forecasted to reach €38.71m in 2024.
  • The revenue is anticipated to exhibit an annual growth rate (CAGR 2024-2029) of 4.17%, leading to a market volume of €47.49m by 2029.
  • When compared globally, the United States is expected to generate the highest revenue (€846.70m in 2024).
  • In terms of per person revenues in 2024, €3.02k are generated in relation to the total population figures.
  • South Korea's pharmaceutical cannabis market is gaining traction with increasing research initiatives and growing acceptance of medical cannabis.

Key regions: United States, Spain, Europe, Thailand, Canada

 
Marché
 
Région
 
Comparaison de régions
 
Monnaie
 

Analyst Opinion

The Pharmaceutical Cannabis market in South Korea has been experiencing significant growth in recent years.

Customer preferences:
Customers in South Korea are increasingly turning to Pharmaceutical Cannabis products due to growing awareness of their potential health benefits and therapeutic properties. The shift towards natural and alternative medicine options has also influenced consumer preferences in the country.

Trends in the market:
One of the key trends in the Pharmaceutical Cannabis market in South Korea is the increasing acceptance and legalization of medical cannabis for specific medical conditions. This trend has opened up new opportunities for pharmaceutical companies to develop and market Cannabis-based products in the country. Additionally, the government's efforts to streamline regulations and improve access to medical cannabis have further fueled market growth.

Local special circumstances:
South Korea has a unique regulatory environment when it comes to Cannabis, with strict regulations in place for both medical and recreational use. However, the gradual relaxation of these regulations for medical purposes has created a niche market for Pharmaceutical Cannabis products. The cultural shift towards more holistic approaches to healthcare and the increasing acceptance of alternative medicine have also contributed to the growth of the market in South Korea.

Underlying macroeconomic factors:
The growing demand for Pharmaceutical Cannabis products in South Korea is also influenced by broader macroeconomic factors such as increasing healthcare expenditures, rising chronic diseases, and an aging population. These factors have created a favorable market environment for pharmaceutical companies looking to capitalize on the growing popularity of Cannabis-based treatments in the country.

Methodology

Data coverage:

Data encompasses B2B and B2C enterprises. Figures are based on companies' revenues, funding values and global consumer survey data. Revenues include retail, sales and taxes.

Modeling approach / Market size:

Market sizes are determined by a Top-Down approach, based on a specific rationale for each market market. As a basis for evaluating markets, we use financial reports, third-party data. Next, we use relevant key market indicators and data from country-specific associations such as tobacco spending per capita, medical product spending per capita, consumer spending and consumer spending for recreation purposes, population. This data helps us to estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, S-Curve function, ARIMA time series model and exponential curve function.

Additional Notes:

The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. GCS data is reweighted for representativeness.

Vue d’ensemble

  • Revenue
  • Users
  • Analyst Opinion
  • Global Comparison
  • Methodology
  • Key Market Indicators
Veuillez patienter

Contact

Des questions ? Nous nous ferons un plaisir de vous aider.
Statista Locations
Contact Camille Dubois
Camille Dubois
Customer Relations

Lun - Ven, 9:00 - 18:00 h (EST)

Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (États-Unis)

Lun - Ven, 9:00 - 18:00 h (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asie)

Lun - Ven, 9:00 - 17:00 h (SGT)

Contact Ayana Mizuno
Ayana Mizuno
Junior Business Development Manager– Contact (Asie)

Lun - Ven, 10:00 - 18:00 h (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Lun - Ven, 9:00 - 18:00 h (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Amérique latine)

Lun - Ven, 9:00 - 18:00 h (EST)